Par, Alkermes Sue Breckenridge To Block Generic Megace

Law360, New York (July 2, 2013, 5:07 PM EDT) -- Par Pharmaceutical Inc. and Alkermes Pharma Ireland Ltd. brought patent infringement allegations in New Jersey federal court Thursday against Breckenridge Pharmaceutical Inc. over the company’s plans to make a generic version of the appetite stimulant drug Megace ES.

Par and Alkermes allege Boca Raton, Fla.-based Breckenridge has infringed two patents related to the drug by submitting an abbreviated new drug application seeking U.S. Food and Drug Administration approval to make a generic form of Megace ES. The suit seeks an injunction and compensatory damages.

“Plaintiffs will...
To view the full article, register now.